Analysts to Bayer CEO Start with the simple things, then split up

fiercepharma | June 21, 2019

Analysts to Bayer CEO Start with the simple things, then split up
Bayer CEO Werner Baumann has already put the company on a major overhaul mission to focus on life sciences. But apparently, investors arent satisfied yet. Shareholders are still complaining about how Bayer management is handling the Roundup weedkiller litigation and executives' lack of communication with the market over business information and future stock-moving events, Bernstein analysts Wimal Kapadia and Gunther Zechmann wrote in a letter to Baumann. Their suggestions? “Start with the simple things (communication) and keep going” by settling the Roundup suits, addressing the pharma patent cliff and, last but not least, splitting up. The Bernstein analysts' observation echoes a rare no-confidence vote in management that came out of the company’s annual general meeting in April. There, more than half of shareholders voted against ratifying the Baumann-led executive team’s actions in 2018. One reason? Bayer has made little effort at offering information on the standalone performance progress of Monsanto and the pre-merger crop business, the analysts said. And that doesn't give investors the peace of mind that everything is going according to plan. “In general, information availability vs. peers and willingness to disclose non-material information, is an opportunity for improvement,” they argued. “This matters more than you think.”

Spotlight

Mobile value chain revenues in the US grew 10 percent per annum from 2009 to 2014, and profits rose by as much as 15 percent. The year 2015 is expected to see 3 percent growth in revenues and 6 percent growth in profits.

Spotlight

Mobile value chain revenues in the US grew 10 percent per annum from 2009 to 2014, and profits rose by as much as 15 percent. The year 2015 is expected to see 3 percent growth in revenues and 6 percent growth in profits.

Related News

PHARMACY MARKET

AstraZeneca and R-Pharm sign an agreement to cooperate on COVID-19 vaccine development

AstraZeneca | December 22, 2020

The Russian Direct Investment Fund (RDIF, Russia's sovereign abundance reserve), The Gamaleya National Center, AstraZeneca and R-Pharm have consented to an arrangement focused on the turn of events and usage of a clinical exploration program to survey the immunogenicity and security of the consolidated utilization of one of the segments of the Sputnik V immunization created by the Gamaleya Center, and one of the segments of the AZD1222 antibody, created by AstraZeneca and the University of Oxford. The arrangement was declared on a video-gathering with Vladimir Putin, the President of Russia. The gatherings have likewise consented to create logical and business relations and investigate the opportunities for joint utilization of the Sputnik V antibody and the AZD1222 antibody to make more viable and long haul inoculation against potential new Covid diseases. Clinical preliminaries of the mix of AZD1222 antibody with Sputnik V's human adenoviral vector type Ad26 will start soon. R-Pharm will be among the associations financing the preliminary. Sputnik V is among the world's best and safe immunizations because of its novel innovation consolidating two diverse human adenoviral vectors accommodating a more grounded and longer-term resistant reaction contrasted with antibodies utilizing similar part for the two vaccinations. The routine with two distinctive adenoviral vectors for a prime and a lift vaccination is an extraordinary and momentous disclosure of the Gamaleya Center researchers. It serves to totally dodge invulnerability to the main vector, which is shaped after the principal vaccination, and hence to raise adequacy and make long haul resistance. This routine is one reason why the antibody shows viability of over 90%, with 100% adequacy in serious cases. Among the main COVID-19 antibodies just Sputnik V is utilizing the two-vector innovation.

Read More

VigiLanz launches COVID Quick Start software that gives hospitals customizable real-time alerts and reports to manage viral outbreaks

Prnewswire | May 21, 2020

Hospitals can prepare for additional waves of COVID-19 and flu season in a matter of weeks, with no payments for six months. COVID Quick Start gives hospitals customizable real-time alerts and reports to manage viral outbreaks and exposures. COVID Quick Start uses VigiLanz's clinical surveillance platform to help hospitals adapt to the evolving conditions associated with respiratory viral illnesses. VigiLanz, a clinical surveillance company, today announced COVID Quick Start – a new solution that will enable hospitals to prepare for, prevent, and respond to the spread of COVID-19 and other respiratory viral illnesses. COVID Quick Start gives hospitals customizable real-time alerts and reports to manage viral outbreaks and exposures. Partnering with Datica for rapid deployment and supported by a team of VigiLanz's certified infection preventionists, the software is designed to alleviate the burden on hospital IT resources and clinical staff while increasing patient safety. The solution is available for free for the first six months, with flexible financing options thereafter. COVID Quick Start uses VigiLanz's clinical surveillance platform to help hospitals adapt to the evolving conditions associated with respiratory viral illnesses. The platform continuously pulls patient data from a variety of sources, including EHRs, and evaluates that data against rules that issue real-time alerts to clinical staff. The rules are designed to identify potential respiratory viral illnesses, ensuring early isolation and management of patients, and can also track disease clusters to identify local outbreaks and hospital acquisition. Our team recognized that VigiLanz's software and expertise could be tailored to address the unique issues presented by this pandemic and other potential respiratory viral illnesses, and that we could design a solution with a low barrier to entry, We've built COVID Quick Start as a solution that works both for hospitals with well-funded infection prevention programs, and those where resources may be more restricted. These organizations are facing a possible second wave of COVID-19 on top of the upcoming influenza season. Our Quick Start solution, which provides the basics of what hospitals need to monitor – such as exposures, early case identification, COVID-19 state and federal reporting requirements, and isolation – will help hospitals quickly prepare for what is coming. -Stacy Pur, Vice President of Product Development at VigiLanz Read More: COVID-19 BRINGS DIVISIONS ON HYDROXYCHLOROQUINE, REOPENING Recognizing the urgency for hospitals to have a solution like this in place, COVID Quick Start uses VigiLanz Connect, an API solution for hospital EHRs, powered by Datica, to deliver an even faster integration. This solution minimizes the burden on hospital IT resources and enables COVID Quick Start to begin improving patient safety as quickly as possible. Datica has deep expertise, with over 400 successful EHR integrations," said Dave Levin, MD, Chief Medical Officer at Datica. "We're proud to collaborate with VigiLanz as their EHR integration partner to quickly launch their COVID Quick Start product." COVID Quick Start provides an easy and low-risk entry to the full suite of VigiLanz's SaaS-based clinical surveillance solutions. VigiLanz helps health systems avoid or minimize harm, optimize clinical outcomes, and support preventive care by aggregating and monitoring disparate data in real time from across the EHR and other health system databases. VigiLanz was ranked No. 1 by KLAS Research this year across three categories – Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance. This is the third year in a row it has earned Category Leader designations from KLAS. About VigiLanz Founded in 2001, VigiLanz is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality and safety teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. About Datica Datica is the only managed service provider (MSP) that solves healthcare's biggest roadblocks–EHR integration and cloud compliance. Its integration solution enables data integration from any source, to any destination, in any format - without sacrificing PHI security. Datica's cloud compliance solution offers end-to-end managed services for digital innovators to scale rapidly in the cloud, while ensuring HIPAA compliance and HITRUST certification are in place. With over 400 live integrations and compliant cloud infrastructure for Fortune 500 companies, Datica's deep expertise gives you the confidence and infrastructure to scale quickly and securely. Read More: TOP U.S. HEALTH OFFICIALS SELF-QUARANTINE AFTER COVID-19 CASES IN WHITE HOUSE

Read More

PHARMACY MARKET

Lubrizol Life Science Launches Advanced, Natural Nutraceutical Solution to Support Mental Agility

Lubrizol Life Science | October 28, 2020

Lubrizol Life Science Health (LLS Health) launches ASTAGILE™ microcapsules, its new sustainable, organic-certified, astaxanthin (Haematococcus pluvialis), microencapsulated with spirulina. The two ingredients have been uniquely combined in a patent-pending product designed to promote mental agility and support healthy ageing for young and senior adults. Astaxanthin is a carotenoid found in freshwater microalgae, and spirulina is a type of algae. Both have numerous health promoting effects. To create the synergistic algae blend, LLS Health teamed with Neoalgae Micro Seaweeds Products, SL, a research and development company in Spain dedicated to microalgae biotechnology.

Read More